By Brazil Stock Guide – Fitch Ratings downgraded the national long-term rating of Oncoclínicas to ‘CCC-(bra)’ from ‘BBB(bra)’, removing the negative watch but signaling a sharp deterioration in the company’s credit profile. The move reflects mounting concerns over liquidity, elevated leverage and a growing probability of debt restructuring in the near term.
According to Fitch, Oncoclinicas is expected to end 2025 with cash below R$100 million, excluding restricted balances, while facing R$745 million in debt maturities in 2026 and R$810 million in 2027. The agency estimates the company will need to refinance at least R$1 billion in 2026 to meet obligations and cover projected negative free cash flow. Gross leverage is seen around 6.0x in 2025, easing only gradually thereafter.
A R$1.4 billion debt-to-equity swap completed in November 2025 temporarily relieved covenant pressure, but did not eliminate refinancing risks. Operating cash flow is projected to remain negative — around R$600 million in 2025 and still negative in 2026 — reflecting high working capital needs and financial expenses. Delayed receivables of approximately R$865 million from Unimed-Ferj, renegotiated with significant discounts, continue to weigh on liquidity.
Liquidity Crunch
With gross debt of R$4.8 billion as of September 2025, the company’s capital structure leaves limited room for maneuver. Fitch projects EBITDA (pre-IFRS) between R$600 million and R$700 million in 2025–2026, implying margins of 10%–12%, levels insufficient to materially deleverage in the short term.
Oncoclinicas benefits from structurally rising oncology demand in Brazil — roughly 700,000 new cancer cases annually — providing revenue visibility. Yet, Fitch argues that operational recovery will likely be gradual, while financial stress remains immediate.